Agenda

MASTERCLASS WORKSHOPS
Monday, 4 March 2019
CONFERENCE DAY 1
Tuesday, 5 March 2019
CONFERENCE DAY 2
Wednesday, 6 March 2019

Registration & Networking Breakfast

Developing Your Competitive Expertise: Late-Lifecyle Management & Competitive Uncertainty

This workshop session (with breakouts), will give participants first-hand insights from combined 30+ years of experience dealing with uncertainty and helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets.

PART A: Dealing with uncertainty – Developing robust competitive assumptions with a systematic framework (Comp-ACT)

* Demonstrate the importance of comprehensive & robust threat assessments and the impacts these can have on strategic decision making (commercial readiness, development programs, BD opportunities, forecasting, scenario planning, mitigation plans, etc.)

* Provide attendees insights of a systematic framework-driven process to evaluate competitive threats from in-class/out-class competitor assets, which will ultimately ensure proactive and strategic impact

PART B: Late Lifecycle Management – Gx/Biosimilar Issues, Intelligence Options, and Actions

This interactive workshop session will enable you to:

* Set up a best-in-industry Gx/biosimilar RI and CI tracking program

* Understand Gx / Biosimilar product development and entry strategies

* Identify potential regulatory and legal actions to optimize launches in emerging markets and enforce IPR / exclusivity

Presented by Inovis

Networking Lunch

Best Practices to Create/Write Effective and Impactful CI Reports and Presentations

Presented by Molekule Consulting

Networking Break and Refreshments

Scenario Planning in EMS: How to Build Resilience to the External Environment into the Strategic Plans of Your Decision-Makers

The nature of the competitive threat in healthcare originating from EMS: the types of local competitors and how you can compete against them

Masterclasses/Workshops Conclude

Good Morning! Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Keynote: Future of Pharma in the Era of Big Data and AI

Presented by IBM Watson Health

Keynote: Quintessential Agency Industry Partnership – How to Make it Work!

We will role-play what a good and a more difficult agency / client relationship looks like.

The goal of our “performance” is to provide the audience with an entertaining learning experience.

Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results
The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Chiesi Farmaceutici S.p.A. and Molekule Consulting

Refresh & Connect in Exhibition Hall

Keynote: Executive Level Boardroom Discussions

Presented by Bayer Pharmaceuticals, Chiesi Farmaceutici S.p.A., Debiopharm S.A., Helsinn Healthcare, Merck/MSD, Novo Nordisk A/S, Philips Healthcare, Sanofi, and Vifor Pharma

“Ask the Experts” Interactive Breakout Groups Round 1

(Explore and capture the power of participants’ insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
CI on Generics

Presented by Sandoz

BREAKOUT 2
Competitive Intelligence in the Pharma Emerging Markets: Challenges and Opportunities

With the lack of reliable competitive data in some pharma emerging markets, pharma companies risk making the wrong decisions and launch plans.

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

Presented by Acino International AG

BREAKOUT 3
Importance of Patient Adherence for the Healthcare Players

- the place of patient adherence within the pharmaceutical industry decisions

– measuring patient adherence
– the benefits of more communication about patient adherence

Presented by Unither Pharmaceuticals

BREAKOUT 4
How to Construct Business Case – What to Not Forget

Presented by SOTIO, a.s.

BREAKOUT 5
Increasing FTEs without Increasing FTEs: How to Expand CI Activities within the Company

Presented by Chiesi Farmaceutici S.p.A.

BREAKOUT 6
Growth Journey of a CI Professional - Sharing and Exchanging Experiences and Insights: from Functional to Corporate in Scope, from Ad Hoc to Defined

In this breakout session, Vivian will share some highlights, lessons and insights as a CI professional,

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

Presented by Elanco

BREAKOUT 7
How to Calculate the Return of Investment (ROI) for CI? Is It Even Possible?

• The group will discuss what can be measured when analyzing the impact of CI and the Return of Investment (ROI) for CI.

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

Presented by Molekule Consulting

“Ask the Experts” Interactive Breakout Groups Round 2

(Explore and capture the power of participants’ insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
CI on Generics

Presented by Sandoz

BREAKOUT 2
Competitive Intelligence in the Pharma Emerging Markets: Challenges and Opportunities

With the lack of reliable competitive data in some pharma emerging markets, pharma companies risk making the wrong decisions and launch plans.

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

Presented by Acino International AG

BREAKOUT 3
Importance of Patient Adherence for the Healthcare Players

- the place of patient adherence within the pharmaceutical industry decisions

– measuring patient adherence
– the benefits of more communication about patient adherence

Presented by Unither Pharmaceuticals

BREAKOUT 4
How to Construct Business Case – What to Not Forget

Presented by SOTIO, a.s.

BREAKOUT 5
Increasing FTEs without Increasing FTEs: How to Expand CI Activities within the Company

Presented by Chiesi Farmaceutici S.p.A.

BREAKOUT 6
Growth Journey of a CI Professional - Sharing and Exchanging Experiences and Insights: from Functional to Corporate in Scope, from Ad Hoc to Defined

In this breakout session, Vivian will share some highlights, lessons and insights as a CI professional,

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

Presented by Elanco

BREAKOUT 7
How to Calculate the Return of Investment (ROI) for CI? Is It Even Possible?

• The group will discuss what can be measured when analyzing the impact of CI and the Return of Investment (ROI) for CI.

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

Presented by Molekule Consulting

Networking Luncheon

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Using CI to Predict Approval Timelines

• With the various designations that the FDA grants new therapies, how can we use CI to predict approval timelines?

o Overview of Phase 3 to approval timelines
o Summary of FDA programs to expedite development of new therapies and how they can impact approval timelines
o Using competitive intelligence to inform approval timelines

Presented by Lifescience Dynamics

SESSION TWO

Dealing with Uncertainty – Experiences, Challenges and Opportunities

Within the Pharma industry, Competitive Intelligence is becoming established as providing vital support in enabling strategy and decision making at a cross-functional level.

However, with increasing complexities surrounding competitive assumptions and the opportunities/challenges they impact within a global environment, many CI professionals find it increasingly difficult to move beyond the “information” provider to “thought-partner” for their stakeholders. At INOVIS, we are progressively dealing with clients struggling to deal with the unknown, with the fear of uncertainty greatly contributing to a lack of agility and competitive fitness across organizations.

Join us for a co-presentation with a leading industry expert and INOVIS as we explore these topics and discuss:
 Real-world examples from Pharma professionals, where overarching uncertainties have impacted business issues
– How was uncertainty addressed?
– What are the learnings?
 How can CI – be it a mindset or specific framework(s) – generate actionable and tangible outcomes to support the current pharma business environment?
 What are the opportunities for high-impact/high value vendor-client activities to better support this area?

Participants will benefit from the vast experience of the presenters and take home ideas and practical considerations to immediately implement as part of their working practices. Moreover, by strengthening and leveraging their client relationships, drawing on specific expertise and experience, CI professionals should leave with more confidence in dealing with the unknown and turning these challenging situations to their opportunity!

Presented by Inovis

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Personalized Healthcare - Driving the Pharma/IT Convergence

Presented by Prescient Healthcare Group

SESSION TWO

The Challenge of Uncertain Futures – Integrating CI into Strategic Decision Making

Over a number of years Osprey Health Consulting has recognised the growing challenge facing the CI professional community in defining

the implications of CI in markets where there are multiple possible futures and where uncertainty is increasing. The Osprey Health Consulting presentation will highlight the reasons for increasing uncertainty about the future of markets and how this challenges strategic decision making in pharma. How CI professionals can adapt to this new world to ensure the information they provide facilitates improved decision making will be discussed. The critical role of CI in informing, supporting and validating strategic decision making in real-time assessments of markets will be explored and models of how this can be achieved will be proposed.

Presented by Osprey Health Consulting

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Transformative Innovation - How ‘Big Pharma’ Is Seeking to Replicate the Creativity and Nimbleness of ‘Start-Up Pharma’?

• Ambition horizons and investment in transformative growth

• “Design Thinking” and its application across the whole organisation
• Digital transformation and the rise of the Chief Digital Officer

Presented by Dig Worldwide

SESSION TWO

Are You Acting as a Real Leader? Team Happiness as a Critical Success Factor

When we consider bringing out the best of our team members, we mainly work on improving their skills, knowledge and abilities.

However, as leaders, how much time and effort do we invest in creating the optimal working atmosphere where the happiness becomes the fuel that keeps the motivation running?

Presented by Merz

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Strategic Competitive Intelligence for R&D

Presented by GlaxoSmithKline

SESSION TWO

Nightmare on CI Street - Misinterpretation, Exaggeration and Fabrication in CI: How to Prevent and Implement Damage Control

I will be showing detailed, but blinded case studies to help the CI community learn my lessons to prevent painful

episodes and to ensure success with their CI functions. I am aiming the audience to take my slides and templates I have created over the years to help them with their careers.

Presented by Bayer Pharmaceuticals

Cocktail Reception and Networking

Good Morning! Registration & Networking Breakfast in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Decoding Signals of Development and Disruption

I’ll talk about how with so much tech noise in healthcare going in on now; how teams can spot real trends that lead to disruption and not lose track or derail the strategy due to ‘disruptive’ but otherwise isolated innovation.

Presented by Abbott Established Pharmaceuticals

SESSION TWO

How CI Can Support Strategic Planning

Competitive Intelligence is a critical process in both the short and long term Strategic Planning, providing inputs for the different scenarios build up in the Pharmaceutical and Biotech industry.

Presented by TESARO

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

The Asset Journey: Optimizing Tools and Personnel to Maximize ROI from CI Throughout

Presented by Proactive Worldwide

SESSION TWO

Partnering 100: Key Insights from the Last 100 Deals in BioPharmaceutical Industry

This presentation aims to deliver a few insights to both the sell-side and buy-side CI professionals. Following will be covered

— Trend analysis of different partnering formats (in/out-licensing, Mergers/Acquisitions, R&D Collaborations, Co-Dev/Co-Mktg. alliances) by TA, development stage, valuation etc.
— Identify the top 3-5 deals from the partnering landscape and the underlying strategic drivers
— The most successful deal makers and what makes them so
— Future Outlook: Is the frenzy likely to continue?

Presented by RAS LSS Consulting

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Digital Tools and AI

• Automation and machine learning in R&D

• When and where to apply artificial intelligence
• Innovating in medical affairs, use of eMSL or other digital tools to broaden reach
• Models for conducting clinical trials – in-house vs sourcing
• Application of new digital tools in making clinical trials in smarter ways
• Automated approaches to regulatory intelligence
• Chatbots to provide immediate requests for data and insights, for internal data as well as competitive data

Presented by Novo Nordisk

SESSION TWO

What to Consider When Setting up the Company’s CI Function?

• Deciding on the ambition level

• Leveraging your internal network
• External partners – how to go about it?

Presented by Leo Pharma

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Making the Data and Facts Count: The Importance of High Quality Decision Making within Clinical and Device Development

• Clinical and device development - data and facts in focus

• Focused data reporting in global clinical trials – the importance of looking beyond the obvious
• Selecting or developing a device – comparing available data, identifying solutions, why is it so complex?
• “Success is in the details”

Presented by Idorsia Pharmaceuticals

SESSION TWO

Knowledge Management

Like AI and ML, Knowledge Management has made it back on the pharma stage.

While its precise meaning is open for discussion (and in which field is that not the case), the focus on knowledge and insights, versus managing systems and data, has made it a powerful point of view to address real world challenges in the life science / pharma space. At Roche, for example, several large KM projects have been initiated, that look beyond IT to optimise and structure the information flow across functions and sites. The use of Machine Learning is a tool to improve the quality of the information, and various semantic data integration topics help to identify the insights our R&D colleagues are looking for.

Presented by Roche

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

TBA

SESSION TWO

Decision Making Based on Stochastic Simulation of Drug Development Process

As the services a CMO can provide to the pharma and biotech industry vary according to the lifecycle stage a

molecule is currently found, it becomes crucial to predict the future state of the pharma and biotech projects’ pipeline. Stochastic simulation can be applied to understand the dynamics of the drug development process and to assess how likely certain states are expected to materialize, and such outcomes drive decision making across several business processes at Lonza.

Presented by Lonza

Networking Luncheon

Announcement of Raffle Prize Winners

TBA

Panel Discussion: Launch Strategy

Presented by Bayer, Fresenius Kabi, and Jazz Pharmaceuticals

Livepolling Power Panel: Review and Discussion of the Most Controversial and Important Topics Over the Two Days

Presented by Bayer Pharmaceuticals, Chiesi Farmaceutici S.p.A., Debiopharm S.A., Helsinn Healthcare, Merck/MSD, Novo Nordisk A/S, Philips Healthcare, Sanofi, and Vifor Pharma

Conference Concludes